Watch for the Abaca litigation ruling (potential $7.8M liability exceeding available cash), further Series B conversions that could push shares outstanding above 195M, and whether the stock closes below $0.10 for two more consecutive days triggering Nasdaq delisting. The Opifex deal is highly conditional and non-binding; any definitive agreement will require stockholder vote and Nasdaq approval.
Price Chart
Executive Summary
SHF Holdings (Safe Harbor) reported Q3 2026 revenue of $1.95M (+6.5% YoY) and a net loss of $979,000, swinging from net income of $180,000 in Q3 2025 due to a prior-year debt extinguishment gain. The core business showed modest growth in loan program income (+70.2%) and client deposits, but the filing is dominated by severe capital structure distress: massive dilution from Series B preferred conversions (shares outstanding surged from 1.03M to 132.25M), a going concern disclosure, Nasdaq delisting risk (stock closed below $0.10 for 8 consecutive days), and a proposed reverse-merger with Opifex that would leave existing holders with only ~15% of the combined entity.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $1.95M, +6.5% YoY from $1.83M
- Net loss $979,000 vs net income $180,000 in Q3 2025 (prior year included $3.34M debt extinguishment gain)
- Operating loss narrowed 17.7% to $1.0M from $1.22M
- Loan program income +70.2% to $869,000 on improved revenue-sharing with PCCU
- Shares outstanding exploded from 1,028,702 on Sept 30 to 132,248,520 on Nov 6 due to Series B conversions at $0.1210/share
- 7,605 Series B shares remain, convertible into up to 62.9M additional common shares
- Stock closed below $0.10 for 8 consecutive days; Nasdaq delisting possible before April 19, 2027 compliance deadline
- Going concern disclosure in unaudited financial statements
- Non-binding term sheet with Opifex for reverse merger; existing SHFS holders would get ~15% of combined company
- Cash and cash equivalents $4.4M as of Sept 30, down from $6.78M at Dec 31, 2025
- Operating cash flow -$4.05M for nine months 2026 vs -$2.35M prior year
- Abaca litigation trial held Aug 10-11, 2026; court ruling pending; estimated loss range $0-$7.8M
Financial Impact
Massive dilution: common shares outstanding increased 128x from 1.03M to 132.25M in two weeks. Remaining Series B convertible preferred could add another 62.9M shares. Cash burn continues with $4.05M operating cash outflow YTD. Proposed Opifex deal would dilute legacy holders to ~15% ownership.
Risk Factors
- Imminent Nasdaq delisting if stock closes below $0.10 for 2 more consecutive days (8 of 10 days already met)
- Further dilution from remaining 7,605 Series B shares convertible into 62.9M common shares
- Abaca litigation adverse ruling could exceed available liquidity ($4.4M cash vs $7.8M potential loss)
- Proposed Opifex reverse merger may not close; existing holders face 85% dilution even if it does
- Going concern uncertainty; negative operating cash flow and limited financing options
- Equity line of credit not being drawn while Opifex term sheet is in effect, limiting liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-050636 |
| Exhibit: ex99-2.htm | 0001493152-26-050636 |
| Document: form8-k.htm | 0001493152-26-050636 |
| Document: 0001493152-26-050636-index-headers.html | 0001493152-26-050636 |
| Document: 0001493152-26-050636-index.html | 0001493152-26-050636 |
| Document: 0001493152-26-050636.txt | 0001493152-26-050636 |
| 8-K Data (Synthetic) | 0001493152-26-050636 |
Track record
27 reports on SHFS
13 of 16 bullish or bearish reports moved the stock their way by T+5. Best: +98.49% at T+60 after the Aug 11, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 13, 20263d ago S-1 Bearish 7/10 Entry $0.0277 Now $0.0230 +16.97% settles Nov 23
- Nov 13, 20263d ago DEFA14A Bearish 7/10 Entry $0.0280 Now $0.0230 +17.86% settles Nov 23
- Nov 12, 20264d ago 425 Bearish 7/10 Entry $0.0303 Now $0.0230 +24.09% settles Nov 20
- Nov 12, 20264d ago 8-K Bearish 9/10 Entry $0.0303 Now $0.0230 +24.09% settles Nov 20
- Nov 9, 20267d ago DEFA14A Bearish 7/10 Entry $0.0248 to $0.0230 Now $0.0230 +7.26% ▲ +7.26% +5.57% vs SPY
- Nov 9, 20267d ago 425 Bearish 7/10 Entry $0.0248 to $0.0230 Now $0.0230 +7.26% ▲ +7.26% +5.57% vs SPY
- Nov 9, 20267d ago 8-K Bearish 7/10 Viewing No price data
- Nov 9, 20267d ago Press Release Bearish 7/10 Entry $0.0248 to $0.0230 Now $0.0230 +7.26% ▲ +7.26% +5.57% vs SPY
- Nov 9, 20267d ago Press Release Bearish 7/10 Entry $0.0248 to $0.0230 Now $0.0230 +7.26% ▲ +7.26% +5.57% vs SPY
- Oct 30, 202617d ago 8-K Bearish 7/10 Entry $0.0462 to $0.0248 Now $0.0230 +50.22% ▲ +46.32% +46.40% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers